Healthcare
China's laparoscopic robots sector looks set to benefit from policy updates and hospital procurement. With over 180 certificates expected by mid-2024, tender volumes could double, offering significant growth potential. Domestic manufacturers, including MedBot, are gaining market share with second-generation devices narrowing the gap in stability and cost. Toumai, a product of MedBot with government support and competitive pricing, presents a strong alternative to Intuitive Surgical’s da Vinci system which currently boasts c.90% market share.
Edition: 181
- 08 March, 2024
The rise of Chinese surgical robots
Healthcare
Opportunity for domestic brands amid the expiration of several patents belonging to market leader Intuitive Surgical and its da Vinci robot. Only 0.13% of surgical procedures were performed by robots in China in 2020 (vs. 13% in US). First-mover advantage in branding and costs will be crucial given 30,000 parts the R&D involves and ongoing product iteration. Re. endoscopic surgical robots (the most widely used medical robot), MicroPort and Shandong Wego lead the way with their Toumai and Miaoshou robots which are expected to be approved in 2021-2022.
Edition: 120
- 01 October, 2021
Technology
Pre-IPO research - Medbot is looking to raise around US$1bn in its HK listing. It designs, develops and commercialises surgical robots. The company is pre-revenue but its flagship products are near the registration approval stage. Globally, Intuitive Surgical with a M/Cap of US$100bn+, dominates the market. Intuitive’s products are the industry standard but are expensive which might allow Medbot to penetrate. It is a subsidiary of MicroPort, which will make it easier for it to enter hospitals.
Edition: 117
- 20 August, 2021